LB0006 SPACING OF A TNF BLOCKER AND DOSE REDUCTION OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REMISSION OR LOW DISEASE ACTIVITY WITH OZORALIZUMAB AND METHOTREXATE: A RANDOMISED, CONTROLLED TRIAL (SORAIRO TRIAL)
Yuki Imai, Yoko Kaneko(Keio University), R. Matsumoto(Taisho Pharmaceutical (Japan)), T. Atsumi(Hokkaido University), Tomohiko Yamamura(Kobe University), Tohru Takeuchi(Osaka University of Pharmaceutical Sciences), Shinichiro Okamoto(Keio University), Yuriko Tanaka, T. Kojima, Koichiro Ohmura(Kyoto University), Shu Hirata, Yuri Sato(Taisho Pharmaceutical (Japan)), Taeko Ishii(Eli Lilly (Japan)), Eiichi Tanaka(Yamagata University)
Cited by 0
Related Papers
Arthritis Critically Dependent on Innate Immune System Players
|Immunity|2002|694
NAK is an IκB kinase-activating kinase
|Nature|2000|374
Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation
|Biology of Blood and Marrow Transplantation|2011|363
Distal Pancreatectomy With En Bloc Celiac Axis Resection for Locally Advanced Pancreatic Body Cancer
|Annals of Surgery|2007|315